Loading organizations...
CRISPR QC has raised $11.6M across 2 funding rounds.
CRISPR QC has raised $11.6M in total across 2 funding rounds.
Founded in 2021 by Ross Bundy and Doctor Kiana Aran, San Diego, California-based CRISPR QC provides a data analytics platform and assay service to help scientists measure and optimize gene-editing experiments. The company utilizes its proprietary CRISPR-Chip technology, a biosensor originally published in Nature Biomedical Engineering, to deliver quantitative insights into guide RNA performance, target recognition, and cleavage efficiency. Currently operating through a service-based model for academic and commercial researchers, the firm holds exclusive gene-editing licensing rights from Cardea Bio. As a long-term strategy, the enterprise aims to transition this biosensor technology into standardized, deployable laboratory equipment similar to commercial spectrophotometers. In January 2023, the synthetic biology startup successfully closed a $1.6 million seed funding round and expanded its board of directors by appointing George Bonaros, Toby Richardson, Doctor Paul Grint, and Chris Yoo.
CRISPR QC has raised $11.6M across 2 funding rounds. Most recently, it raised $10.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 6, 2024 | $10M Series A | Chris YOO | — | Announced |
| Jan 10, 2023 | $1.6M Seed | Serra Ventures | — | Announced |
CRISPR QC has raised $11.6M in total across 2 funding rounds.
CRISPR QC's investors include Chris Yoo, Serra Ventures.
